Benzinga's Top Upgrades, Downgrades For August 20, 2020

Upgrades

• For Cinemark Holdings Inc CNK, Benchmark upgraded the previous rating of Hold to the current rating Buy. For the second quarter, Cinemark Hldgs had an EPS of $1.27, compared to year-ago quarter EPS of $0.86. The stock has a 52-week-high of $39.81 and a 52-week-low of $5.71. At the end of the last trading period, Cinemark Hldgs closed at $11.14.
• For OGE Energy Corp OGE, Guggenheim upgraded the previous rating of Neutral to the current rating Buy. OGE Energy earned $0.51 in the second quarter, compared to $0.50 in the year-ago quarter. The stock has a 52-week-high of $46.43 and a 52-week-low of $23.00. At the end of the last trading period, OGE Energy closed at $32.08.
• According to Northland Capital Markets, the prior rating for Power Integrations Inc POWI was changed from Underperform to Market Perform. For the second quarter, Power Integrations had an EPS of $0.66, compared to year-ago quarter EPS of $0.56. At the moment, the stock has a 52-week-high of $127.39 and a 52-week-low of $56.88. Power Integrations closed at $57.30 at the end of the last trading period.
• According to DBS Bank, the prior rating for Sea Ltd SE was changed from Sell to Buy. For the second quarter, Sea had an EPS of $0.68, compared to year-ago quarter EPS of $0.68. At the moment, the stock has a 52-week-high of $154.25 and a 52-week-low of $26.41. Sea closed at $150.58 at the end of the last trading period.
• For Shake Shack Inc SHAK, Wedbush upgraded the previous rating of Neutral to the current rating Outperform. For the second quarter, Shake Shack had an EPS of $0.45, compared to year-ago quarter EPS of $0.27. The current stock performance of Shake Shack shows a 52-week-high of $105.84 and a 52-week-low of $30.01. Moreover, at the end of the last trading period, the closing price was at $53.87.
• According to Barclays, the prior rating for Dana Inc DAN was changed from Equal-Weight to Overweight. In the second quarter, Dana showed an EPS of $0.69, compared to $0.87 from the year-ago quarter. The stock has a 52-week-high of $19.21 and a 52-week-low of $4.22. At the end of the last trading period, Dana closed at $13.17.
• For Elanco Animal Health Inc ELAN, Morgan Stanley upgraded the previous rating of Equal-Weight to the current rating Overweight. For the second quarter, Elanco Animal Health had an EPS of $0.09, compared to year-ago quarter EPS of $0.28. At the moment, the stock has a 52-week-high of $32.66 and a 52-week-low of $15.17. Elanco Animal Health closed at $25.80 at the end of the last trading period.

Downgrades

• For Vipshop Holdings Ltd VIPS, JP Morgan downgraded the previous rating of Overweight to the current rating Neutral. For the second quarter, Vipshop Holdings had an EPS of $0.27, compared to year-ago quarter EPS of $0.23. The stock has a 52-week-high of $24.46 and a 52-week-low of $7.69. At the end of the last trading period, Vipshop Holdings closed at $19.26.
• According to Raymond James, the prior rating for Ventas Inc VTR was changed from Strong Buy to Outperform. Ventas earned $0.77 in the second quarter, compared to $0.97 in the year-ago quarter. At the moment, the stock has a 52-week-high of $75.40 and a 52-week-low of $13.35. Ventas closed at $40.38 at the end of the last trading period.
• According to Benchmark, the prior rating for Regeneron Pharmaceuticals Inc REGN was changed from Buy to Hold. For the second quarter, Regeneron Pharmaceuticals had an EPS of $7.16, compared to year-ago quarter EPS of $6.04. The current stock performance of Regeneron Pharmaceuticals shows a 52-week-high of $664.64 and a 52-week-low of $271.37. Moreover, at the end of the last trading period, the closing price was at $629.63.
• For Biomarin Pharmaceutical Inc BMRN, RBC Capital downgraded the previous rating of Outperform to the current rating Sector Perform. Biomarin Pharmaceutical earned $0.16 in the second quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Biomarin Pharmaceutical shows a 52-week-high of $131.94 and a 52-week-low of $62.88. Moreover, at the end of the last trading period, the closing price was at $76.72.
• Wells Fargo downgraded the previous rating for Crown Castle International Corp CCI from Overweight to Equal-Weight. In the second quarter, Crown Castle Intl showed an EPS of $1.45, compared to $1.41 from the year-ago quarter. The stock has a 52-week-high of $180.00 and a 52-week-low of $114.18. At the end of the last trading period, Crown Castle Intl closed at $162.69.
• For Momenta Pharmaceuticals Inc MNTA, Stifel downgraded the previous rating of Buy to the current rating Hold. Momenta Pharmaceuticals earned $0.48 in the second quarter, compared to $1.16 in the year-ago quarter. The current stock performance of Momenta Pharmaceuticals shows a 52-week-high of $52.21 and a 52-week-low of $11.91. Moreover, at the end of the last trading period, the closing price was at $52.12.
• For Principia Biopharma Inc PRNB, Stifel downgraded the previous rating of Buy to the current rating Hold. Principia Biopharma earned $0.31 in the second quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $100.04 and a 52-week-low of $25.35. At the end of the last trading period, Principia Biopharma closed at $99.70.
• For Teligent Inc TLGT, Craig-Hallum downgraded the previous rating of Buy to the current rating Hold. Teligent earned $1.54 in the second quarter, compared to $0.04 in the year-ago quarter. At the moment, the stock has a 52-week-high of $5.94 and a 52-week-low of $0.19. Teligent closed at $2.01 at the end of the last trading period.
• Credit Suisse downgraded the previous rating for Sarepta Therapeutics Inc SRPT from Outperform to Neutral. In the second quarter, Sarepta Therapeutics showed an EPS of $1.51, compared to $0.83 from the year-ago quarter. The stock has a 52-week-high of $175.00 and a 52-week-low of $72.05. At the end of the last trading period, Sarepta Therapeutics closed at $148.66.

Initiations

• Deutsche Bank initiated coverage on Check Point Software Technologies Ltd CHKP with a Hold rating. The price target for Check Point Software is set to $128.00. Check Point Software earned $1.58 in the second quarter, compared to $1.38 in the year-ago quarter. The current stock performance of Check Point Software shows a 52-week-high of $130.65 and a 52-week-low of $80.06. Moreover, at the end of the last trading period, the closing price was at $128.08.
• With a current rating of Outperform, Evercore ISI Group initiated coverage on 8x8 Inc EGHT. The price target seems to have been set at $23.00 for 8x8. 8x8 earned $0.07 in the first quarter, compared to $0.14 in the year-ago quarter. The stock has a 52-week-high of $25.25 and a 52-week-low of $10.70. At the end of the last trading period, 8x8 closed at $16.28.
• Morgan Stanley initiated coverage on ACADIA Pharmaceuticals Inc ACAD with an Overweight rating. The price target for ACADIA Pharmaceuticals is set to $55.00. In the second quarter, ACADIA Pharmaceuticals showed an EPS of $0.27, compared to $0.38 from the year-ago quarter. The current stock performance of ACADIA Pharmaceuticals shows a 52-week-high of $58.72 and a 52-week-low of $23.77. Moreover, at the end of the last trading period, the closing price was at $38.91.
• Deutsche Bank initiated coverage on Fortinet Inc FTNT with a Hold rating. The price target for Fortinet is set to $131.00. Fortinet earned $0.82 in the second quarter, compared to $0.58 in the year-ago quarter. The current stock performance of Fortinet shows a 52-week-high of $151.95 and a 52-week-low of $70.20. Moreover, at the end of the last trading period, the closing price was at $129.51.
• Needham initiated coverage on Vir Biotechnology Inc VIR with a Buy rating. The price target for Vir Biotechnology is set to $62.00. Vir Biotechnology earned $0.27 in the second quarter. At the moment, the stock has a 52-week-high of $75.00 and a 52-week-low of $11.65. Vir Biotechnology closed at $50.43 at the end of the last trading period.
• Morgan Stanley initiated coverage on Evofem Biosciences Inc EVFM with a Equal-Weight rating. In the second quarter, Evofem Biosciences showed an EPS of $0.39, compared to $0.95 from the year-ago quarter. The stock has a 52-week-high of $7.50 and a 52-week-low of $2.73. At the end of the last trading period, Evofem Biosciences closed at $3.36.
• With a current rating of In-Line, Evercore ISI Group initiated coverage on Five9 Inc FIVN. The price target seems to have been set at $122.00 for Five9. For the second quarter, Five9 had an EPS of $0.21, compared to year-ago quarter EPS of $0.20. The stock has a 52-week-high of $131.98 and a 52-week-low of $50.73. At the end of the last trading period, Five9 closed at $124.59.
• Oppenheimer initiated coverage on Fulgent Genetics Inc FLGT with an Outperform rating. The price target for Fulgent Genetics is set to $75.00. Fulgent Genetics earned $0.17 in the second quarter, compared to $0.06 in the year-ago quarter. At the moment, the stock has a 52-week-high of $47.85 and a 52-week-low of $6.70. Fulgent Genetics closed at $44.01 at the end of the last trading period.
• Goldman Sachs initiated coverage on Flexion Therapeutics Inc FLXN with a Neutral rating. The price target for Flexion Therapeutics is set to $15.00. Flexion Therapeutics earned $0.76 in the second quarter, compared to $0.96 in the year-ago quarter. The current stock performance of Flexion Therapeutics shows a 52-week-high of $22.98 and a 52-week-low of $5.01. Moreover, at the end of the last trading period, the closing price was at $12.65.
• With a current rating of Overweight, Wells Fargo initiated coverage on Tandem Diabetes Care Inc TNDM. The price target seems to have been set at $120.00 for Tandem Diabetes Care. For the second quarter, Tandem Diabetes Care had an EPS of $0.45, compared to year-ago quarter EPS of $0.03. The stock has a 52-week-high of $110.80 and a 52-week-low of $43.69. At the end of the last trading period, Tandem Diabetes Care closed at $107.33.
• Berenberg initiated coverage on Eaton Corp PLC ETN with a Hold rating. The price target for Eaton Corp is set to $110.00. Eaton Corp earned $0.70 in the second quarter, compared to $1.53 in the year-ago quarter. At the moment, the stock has a 52-week-high of $105.78 and a 52-week-low of $56.41. Eaton Corp closed at $100.48 at the end of the last trading period.
• With a current rating of Buy, Berenberg initiated coverage on Emerson Electric Co EMR. The price target seems to have been set at $83.00 for Emerson Electric. For the third quarter, Emerson Electric had an EPS of $0.80, compared to year-ago quarter EPS of $0.94. The current stock performance of Emerson Electric shows a 52-week-high of $78.38 and a 52-week-low of $37.75. Moreover, at the end of the last trading period, the closing price was at $68.32.
• With a current rating of Buy, Berenberg initiated coverage on Rockwell Automation Inc ROK. The price target seems to have been set at $270.00 for Rockwell Automation. In the third quarter, Rockwell Automation showed an EPS of $1.27, compared to $2.40 from the year-ago quarter. At the moment, the stock has a 52-week-high of $238.49 and a 52-week-low of $115.38. Rockwell Automation closed at $228.68 at the end of the last trading period.